Drug Trial Radar · NCT01986088
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,008
Actual
Start
Nov 1996
Primary completion
Jan 1998
Study completion Jan 1998
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack. The goal of the current study was to extend the findings of that study by examining the efficacy of eletriptan compared with both 50- and 100-mg doses of sumatriptan; and to evaluate the comparative efficacy of eletriptan and sumatriptan across additional important clinical outcomes. In particular, early response (at 1 hour), sustained response (without need for additional treatment) at 24 hours, and consistency of response across multiple attacks were examined.
Conditions
- Migraine With or Without Aura
Interventions
PlaceboDrug
matching placebo
Eletriptan 40 mgDrug
40mg oral
Eletriptan 80 mgDrug
80mg oral
Sumatriptan 50 mgDrug
50mg oral
Sumatriptan 100 mgDrug
100mg oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Headache response at 1 hour after treatment of the first attack.Time frame: 1 hour
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.